HPB & Spleen · 27 March 2026

AI-Driven Marker Improves Outcomes for Pancreatic Cancer Nonproducers

A new AI-derived tumor marker can enhance treatment response assessment in pancreatic cancer patients who do not produce elevated CA19-9.

In a study of 121 patients, a 50% or more decline in the marker (e19-9) was linked to a 5-fold higher likelihood of completing neoadjuvant therapy and surgery.
An e19-9 level below 100 significantly correlated with improved overall survival (hazard ratio 0.49).

Consider integrating e19-9 monitoring into clinical practice for nonproducing CA19-9 patients to optimize treatment planning and prognostication.

Journal Article by Thalji SZ, Aldakkak M (…) Kothari AN et 18 al. in JAMA Surg

read the whole article in JAMA Surg

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in HPB & Spleen.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

The latest stitches

Ann Surg Oncol2 Nov 2026

Pancreatic ductoscopy guides tissue preservation

In two older patients having robotic surgery for a pancreatic growth, ductoscopy and checks of the cut edge let surgeons leave the remaining pancreas in place.

HPB & Spleen30 Oct 2026

Intrahepatic cholangiocarcinoma has more options

Resection remains central, but care now includes preoperative therapy, liver-directed treatments and drugs matched to tumor changes.

Ann Surg Oncol29 Oct 2026

Pancreatic cancer: longer survival with combined treatment

For locally advanced pancreatic cancer, cryoablation plus drug treatment was linked to longer median survival than drug treatment alone, but the result does not prove benefit.

All papers in HPB & Spleen →